{"filings":[{"id":536117,"accession_number":"0001764013-26-000062","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2026-05-20T11:14:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant posts $0.73/sh Q4 loss; IMVT-1402 hits 72.7% ACR20 in D2T RA at Week 16","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IMVT-1402 in D2T RA: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at Week 16; open-label, blinded assessors; safety well-tolerated.","Cash $902.1M as of Mar 31, 2026; provides runway to potential launch of IMVT-1402 in GD.","Net loss Q4 FY2026 $147.9M ($0.73/share) vs $106.4M ($0.64/share) YoY; FY net loss $505.6M ($2.77/share).","Batoclimab discontinued after Phase 3 TED miss; $39M contract cost recognized in Q4.","CLE proof-of-concept fully enrolled; topline data expected H2 2026. Other trials on track for GD, MG, CIDP, SjD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108214,"accession_number":"0001764013-26-000010","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports Q3 net loss of $110.6M; cash $994.5M; D2T RA trial fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $110.6M ($0.61/sh) for Q3 FY26; non-GAAP net loss $97.5M.","Cash and equivalents $994.5M post-$550M financing; runway to GD commercial launch.","D2T RA potentially registrational trial fully enrolled; topline data H2 2026.","Batoclimab Phase 3 TED data expected H1 2026; IMVT-1402 GD and MG topline in 2027.","R&D expenses $98.9M, up from $94.5M YoY; driven by IMVT-1402 clinical activities."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124652,"accession_number":"0001193125-25-317577","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunovant raises $550M via 26.2M share offering at $21.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$550M from 26.2M shares priced at $21.00/share.","Controlling stockholder Roivant Sciences Ltd. participated in the offering.","Offering closed December 12, 2025; Leerink Partners acted as underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124651,"accession_number":"0001193125-25-314994","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immunovant prices $550M stock offering; updates IMVT-1402 and batoclimab timelines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten common stock offering of ~$550M gross proceeds; Roivant Sciences to purchase shares; expected close Dec 12, 2025.","Potentially registrational D2T RA trial of IMVT-1402: top-line results now expected in 2026 (previously initial open-label only in 2026).","Batoclimab Phase 3 TED studies: top-line results delayed to H1 2026 (previously by end of 2025); results shared concurrently.","Discussions commenced with HanAll to potentially return batoclimab rights; may result in dispute or arbitration.","Existing cash plus offering proceeds expected to fund operations through potential commercial launch of IMVT-1402 in Graves' Disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124650,"accession_number":"0001764013-25-000153","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunovant CMO Michael Geffner departs; consulting through April 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Geffner, M.D., M.B.A., ceased as Chief Medical Officer effective Nov 21, 2025.","Departure is part of R&D leadership restructuring under CEO Eric Venker.","Severance per existing employment agreement; consulting services through April 30, 2026.","Outstanding equity awards continue vesting during consulting period; accelerated vesting on change in control.","Option exercise period extended to nine months after consulting ends or original expiration, whichever earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124649,"accession_number":"0001764013-25-000148","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant Q2 loss $126.5M; batoclimab TED readout delayed to H1 2026; cash $521.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $126.5M ($0.73/share) in fiscal Q2 ended Sep 30, 2025, vs $109.1M ($0.74) prior year.","Cash and equivalents $521.9M providing runway through GD readout expected in 2027.","Batoclimab Phase 3 TED: first readout delayed; both studies now expected to report concurrently H1 2026.","IMVT-1402 GD study showed first-ever potentially disease-modifying therapy with 6-month off-treatment data.","Topline results for IMVT-1402 in D2T RA and CLE expected 2026; GD, MG, D2T RA in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141340,"accession_number":"0001764013-25-000136","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.","50% (8/17) of responders achieved anti-thyroid drug-free remission at six months off-treatment.","Two registrational trials for lead compound IMVT-1402 in Graves' disease are enrolling with topline data expected in 2027.","Immunovant will host an investor call on September 3, 2025, at 4:30 p.m. EDT to discuss the data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141339,"accession_number":"0001764013-25-000132","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunovant shareholders elect all three director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jacob Bauer, Douglas Hughes, and Robert Susman elected to Board until 2026 annual meeting.","Ernst & Young ratified as independent auditor for FY ending March 31, 2026 (165.4M for, 7K against).","Non-binding advisory vote on named executive officer compensation approved (159.0M for, 1.2M against).","Approximately 97% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141338,"accession_number":"0001764013-25-000128","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant Q1 net loss $120.6M; initiates two registrational trials for IMVT-1402","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $598.9M provides runway through Graves' disease readout expected in 2027.","Net loss $120.6M ($0.71/share) vs $87.2M ($0.60) in prior-year quarter.","Initiated a second potentially registrational trial of IMVT-1402 in Graves' disease in June 2025.","Initiated a potentially registrational trial of IMVT-1402 in Sjögren's disease in June 2025.","Expects GD remission data from batoclimab proof-of-concept study at ATA meeting in September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141337,"accession_number":"0001764013-25-000121","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunovant finalizes CEO Eric Venker's employment agreement with $672K salary, equity awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary $672,000; target annual bonus 72.25% of base salary.","Option Awards: 1,300,000 stock options and options valued at $2,250,000 (189,900 shares), four-year vest.","CVAR Award: 1,475,000 capped appreciation rights with performance and $16.76 stock price hurdle.","Two-year holding period on vested shares from Unit Option Award and 87.25% of CVAR-settled shares.","Severance: 12 months salary + target bonus + COBRA if terminated without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159144,"accession_number":"0001764013-25-000091","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant Q4 FY2025 net loss $106.4M, cash $714M; new CEO Eric Venker","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $106.4M ($0.64/share) for Q4 FY2025, vs $75.3M ($0.52/share) a year ago.","Cash and equivalents $714M as of March 31, 2025; runway through GD readout expected in 2027.","Eric Venker, M.D. appointed CEO and Tiago Girao CFO in April 2025 as part of strategic transition.","R&D expenses $93.7M in Q4, up from $66.1M, driven by IMVT-1402 clinical trial costs.","Potentially registrational trials for IMVT-1402 in Sjögren's disease and second GD trial planned summer 2025."],"consensus_eps_estimate":-0.7285,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159143,"accession_number":"0001764013-25-000078","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Immunovant appoints new CEO/CFO, expands IMVT-1402 into Sjögren's and CLE","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Peter Salzmann retired; Eric Venker (Roivant President) appointed CEO, effective April 21.","CFO Renee Barnett stepped down; Tiago Girao appointed CFO with $481K salary and $6.66M equity award.","Board changes: George Migausky resigned; Robert Susman and Jacob Bauer appointed as directors.","IMVT-1402 IND cleared for potential registrational study in Sjögren's disease, start summer 2025.","Proof-of-concept study in Cutaneous Lupus Erythematosus initiated; cash runway through Graves' readout in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177609,"accession_number":"0001764013-25-000037","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Batoclimab meets MG Phase 3 primary endpoint; CIDP shows 84% responder rate with >70% IgG reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MG Phase 3: 680mg batoclimab arm achieved 5.6-point MG-ADL improvement vs 3.6 placebo (p<0.001).","Minimal Symptom Expression (MSE) at Week 12: 42% for 680mg, 31% for 340mg, 7% placebo.","CIDP Phase 2b Period 1: 1.8-point aINCAT improvement; 84% responder rate among patients with ≥70% IgG reduction.","Company will not seek batoclimab approval in MG/CIDP; focusing on IMVT-1402 and awaiting thyroid eye disease data.","IND cleared for IMVT-1402 in MG and CIDP; registrational studies expected to start imminently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177608,"accession_number":"0001764013-25-000024","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports Q3 net loss $111.1M; cash $374.7M plus $450M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $111.1M ($0.76/sh) vs $51.4M ($0.36) y/y; R&D spend $94.5M up from $48.3M on IMVT-1402 prep.","Pro forma cash ~$825M after $450M private placement closed Jan 15, 2025.","Batoclimab MG pivotal and CIDP period 1 results expected by March 31, 2025.","IMVT-1402: 6 INDs cleared; pivotal GD and D2T RA studies enrolling with autoinjector.","Batoclimab GD additional data (6-month remission) summer 2025; TED top-line H2 2025."],"consensus_eps_estimate":-0.7315,"consensus_eps_actual":-2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177607,"accession_number":"0001193125-25-012329","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunovant files prospectus supplement to register 5.65M shares for resale by selling stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to register up to 5,654,990 shares of common stock for resale by selling stockholders.","Shares were acquired by selling stockholders in private placement financing reported on January 13, 2025.","Opinion of counsel Cooley LLP regarding legality of shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177606,"accession_number":"0001764013-25-000009","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant presents corporate overview at J.P. Morgan Healthcare Conference; no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation on January 14, 2025 covers autoimmune pipeline and tailored science approach.","No specific clinical results, financial updates, or guidance changes provided in the filing.","Filed under Regulation FD; presentation not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177605,"accession_number":"0001764013-25-000007","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Immunovant announces $450M PIPE at $20/share to advance pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to sell 22.5M shares at $20/share to three institutional investors, including Roivant Sciences.","Gross proceeds expected ~$450M; closing on or about Jan 15, 2025 subject to customary conditions.","Proceeds to fund development pipeline (lead asset IMVT-1402), working capital, and general corporate purposes.","Shares sold in private placement exempt from registration; resale registration to be filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194309,"accession_number":"0001764013-24-000183","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunovant announces five IND clearances for IMVT-1402 and plans to initiate registrational trials by March 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Five INDs cleared for IMVT-1402 across therapeutic areas including Graves' disease and rheumatoid arthritis.","Proof-of-concept data from batoclimab in Graves' disease showed 60% response rate at week 2; registrational trial for IMVT-1402 expected by year-end 2024.","Initiation of potentially registrational trial for IMVT-1402 in difficult-to-treat RA expected by March 31, 2025.","Batoclimab trials in MG and CIDP fully enrolled; data disclosures by March 31, 2025.","Appointed Melanie Gloria as COO effective Nov 18, 2024; net loss $109.1M for quarter ended Sept 30, 2024."],"consensus_eps_estimate":-0.6574,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210649,"accession_number":"0001764013-24-000162","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunovant reports 76% response rate in Graves' Disease Phase 2a; IND cleared for IMVT-1402 pivotal trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["High-dose batoclimab (680 mg SC weekly) achieved 76% response rate and 56% ATD-free response at week 12 in patients uncontrolled on antithyroid drugs.","Lower-dose batoclimab (340 mg) yielded 68% response and 36% ATD-free response; 70%+ IgG reduction linked to nearly 3x higher ATD-free response.","FDA IND cleared; pivotal trial of IMVT-1402 in Graves' Disease expected to initiate by December 31, 2024.","Real-world claims data indicate 25–30% of GD patients per year are uncontrolled on ATDs with limited existing therapeutic options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210648,"accession_number":"0001764013-24-000150","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunovant stockholders elect directors, ratify auditor, approve compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three directors (Salzmann, Migausky, Hughes) elected with over 97M votes for each, ~6.5M broker non-votes.","Ernst & Young ratified as auditor for FY ending March 31, 2025: 138,241,628 for, 16,740 against.","Non-binding advisory approval of named executive officer compensation: 128,494,310 for, 3,249,170 against.","Approximately 95% of eligible shares (138.3M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210647,"accession_number":"0001764013-24-000147","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports Q1 FY2025 net loss $87.2M; completes batoclimab MG enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $87.2M ($0.60/share) vs $73.9M ($0.57) YoY; cash $560M as of June 30, 2024.","R&D expenses $75.5M, up 49% YoY, driven by IMVT-1402 prep and batoclimab trials.","Completed enrollment in batoclimab pivotal MG trial; top-line results expected by March 31, 2025.","Plans to initiate 4-5 potentially registrational programs for IMVT-1402 by March 31, 2025; 3 IND applications active by end-2024.","Graves' disease program update expected fall 2024; batoclimab TED top-line data in H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229011,"accession_number":"0001764013-24-000107","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports Q4 net loss $75.3M, cash $635M; plans 4-5 registrational IMVT-1402 studies by 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $75.3M ($0.52/sh) for Q4 FY2024 vs $59.4M ($0.46/sh) YoY; FY net loss $259.3M ($1.88/sh).","Cash and equivalents $635M as of March 31, 2024; R&D expenses $66.1M in Q4.","Following FDA Type B meeting, on track to initiate 4-5 registrational studies for IMVT-1402 by March 31, 2025.","Batoclimab MG topline results expected by end of fiscal 2025; CIDP trial extended ~2 quarters before unblinding.","Composition-of-matter patent for IMVT-1402 issued with term through June 2043."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247620,"accession_number":"0001764013-24-000025","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports Q3 net loss $51.4M; plans 4-5 registrational trials for IMVT-1402","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $51.4M ($0.36/share) vs $63.2M ($0.49) a year ago; cash & equivalents $691M.","IMVT-1402 Phase 1 showed 74% IgG reduction with no/minimal albumin or LDL changes vs placebo.","Plans to start 4-5 potentially registrational IMVT-1402 programs by Mar 2025, 10 indications by Mar 2026.","Batoclimab Phase 3 MG data expected 2H 2024; TED data 1H 2025; Phase 2b CIDP data 2Q/3Q 2024.","R&D spend $48.3M in Q3, up from $42.3M, driven by IMVT-1402 development costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247619,"accession_number":"0001764013-24-000003","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant corporate presentation at J.P. Morgan Healthcare Conference; no specific details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Immunovant presented a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.","Presentation title indicates focus on autoimmune diseases: 'Targeted science, Tailored solutions for people with autoimmune disease'.","Specific pipeline data, financials, or guidance are not included in the exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265083,"accession_number":"0001764013-23-000159","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunovant reports positive initial Phase 2 data for batoclimab in Graves' disease; IgG reduction up to 87%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial cohort in Phase 2 trial exceeded 50% response rate; response defined as normalization of T3/T4 without increasing ATD dose.","680 mg SC batoclimab showed IgG reduction up to 87% (mean 81%) after 12 weeks; 340 mg produced lower IgG reductions.","Dose response observed on anti-TSHR autoantibodies and clinical parameters including ATD dose reduction/discontinuation.","Batoclimab generally well tolerated with no new safety signals.","CEO says intent to focus future Graves' development on IMVT-1402, with plans announced later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265082,"accession_number":"0001764013-23-000150","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunovant reports positive IMVT-1402 600 mg Phase 1 data: 74% IgG reduction, placebo-like albumin/LDL-C","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four weekly 600 mg SC doses of IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% at 680 mg.","No significant changes in serum albumin or LDL-C at Day 29 (p>0.05), consistent with placebo-like profile.","All doses well tolerated; only mild or moderate treatment-emergent adverse events observed.","Company expects ~80% steady-state IgG reduction with continued weekly 600 mg dosing after 6-8 weeks.","Immunovant says profile supports broad portfolio of first-in-class and best-in-class FcRn indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265081,"accession_number":"0001764013-23-000131","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports Q2 FY2024 net loss of $58.7M; Phase 1 data supports IMVT-1402 best-in-class potential","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $58.7M ($0.45/share) for Sep Q, vs. $47.9M ($0.41) a year ago; wider loss on higher R&D.","Initial Phase 1 data for IMVT-1402 showed dose-dependent IgG reductions without significant albumin or LDL changes.","Raised ~$467M net in October 2023 public/private offering; pro forma cash $737M as of Sep 30.","Expects initial 600mg MAD cohort data for IMVT-1402 in Nov 2023; Phase 2 Graves' data by year-end 2023.","Phase 3 MG top-line data expected H2 2024; TED data H1 2025; CIDP Phase 2b data H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282284,"accession_number":"0001193125-23-245815","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Immunovant Prices $280M Public Offering; Roivant Commits $170M Private Placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 7,370,000 shares at $38.00/share; gross proceeds ~$280.1M.","Roivant Sciences, majority stockholder, to purchase 4,473,684 shares at same price; proceeds ~$170M.","Combined gross proceeds ~$450M before expenses; expected closing October 2, 2023.","Underwriters granted 30-day option to buy up to 1,105,500 additional shares.","Private placement exempt from registration under Section 4(a)(2) of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282283,"accession_number":"0001764013-23-000114","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunovant announces positive initial Phase 1 data for IMVT-1402 with IgG reductions and no albumin or LDL-C changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean total IgG reduction of 63% after four weekly 300 mg SC doses of IMVT-1402 in Phase 1 MAD cohort.","No decrease in serum albumin below baseline or increase in LDL-C above baseline observed after 4 weeks.","Subcutaneous doses of IMVT-1402 achieved peak IgG reductions similar to those previously seen with batoclimab.","All adverse events were mild or moderate; dosing for 600 mg cohort has recently begun.","Immunovant hosted a conference call and webcast on September 26, 2023 to discuss the data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282282,"accession_number":"0001764013-23-000097","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunovant shareholders elect three directors, ratify EY, approve exec compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Peter Salzmann (98.5M for, 17.7M withheld), Douglas Hughes (96.6M for, 19.6M withheld), George Migausky (96.6M for, 19.7M withheld) elected to board.","Ratification of Ernst & Young as independent auditor for FY2024: 121,206,460 for, 5,261 against, 1,355 abstain.","Non-binding advisory approval of named executive officer compensation: 115,397,185 for, 825,452 against, 8,173 abstain, 4,982,266 broker non-votes.","Annual meeting turnout ~93% of outstanding shares (121,213,076 shares represented).","All three proposals passed; no material changes to governance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282281,"accession_number":"0001764013-23-000090","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports Q1 net loss of $73.9M; IMVT-1402 Phase 1 data on track for September 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $73.9M ($0.57/share) vs $40.4M ($0.35/share) in prior year; cash $330M funds ops into H2 2025.","R&D expenses rose to $50.6M (from $28.4M) driven by IMVT-1402 development and batoclimab milestones.","IMVT-1402 Phase 1 single-ascending dose data expected Sept 2023; multiple-ascending dose data Oct/Nov 2023.","Batoclimab Phase 3 MG data H2 2024; Phase 3 TED data H1 2025; CIDP Phase 2b initial data H1 2024; GD proof-of-concept Q4 2023.","Acquired IPR&D expenses $12.5M from batoclimab milestone achievement under HanAll agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301431,"accession_number":"0001764013-23-000063","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunovant reports FY2023 net loss $211M; IMVT-1402 IND cleared, Phase 1 started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $59.4M ($0.46/share) for Q4 FY2023 vs $47.2M ($0.41) a year ago.","Full-year net loss $211.0M ($1.71/share) vs $156.7M ($1.43); cash $376.5M funding into H2 2025.","R&D expenses rose 61% YoY to $160.3M, driven by batoclimab and IMVT-1402 programs.","FDA IND and MEDSAFE CTA cleared for IMVT-1402; Phase 1 trial enrolling in New Zealand.","Initial Phase 1 data from single-ascending dose expected Aug/Sep 2023; MAD data Oct/Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321250,"accession_number":"0001764013-23-000026","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunovant files 8-K with corporate presentation; no material updates disclosed in filing or exhibit text.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Immunovant released a new corporate presentation for investor business updates on March 27, 2023.","No financial results, clinical data, or guidance changes are included in the 8-K or its sole exhibit (cover page only).","The presentation content is not fully reproduced; material updates, if any, are not evident from the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321249,"accession_number":"0001764013-23-000020","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant reports widened Q3 net loss of $63.2M; cash $432.6M; batoclimab trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.2M ($0.49/share) vs $41.4M ($0.36) prior year; R&D spend rose to $42.3M.","Cash $432.6M expected to fund operations into second half of calendar 2025.","Phase 1 trial of IMVT-1402 to start early 2023; initial data expected mid-2023.","Phase 3 batoclimab in TED initiated; Phase 2b in CIDP started; topline results H1 2025 and H1 2024.","Batoclimab development for warm AIHA discontinued; indication reserved for IMVT-1402."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321248,"accession_number":"0001764013-23-000003","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunovant presents at J.P. Morgan Healthcare Conference with new corporate deck; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation at 41st Annual J.P. Morgan Healthcare Conference beginning January 9, 2023.","New corporate presentation provided to investors; no clinical or financial updates in filing.","Filing does not contain specific new data or material changes to pipeline or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339356,"accession_number":"0001764013-22-000143","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant presents at LifeSci Capital fireside chat; no material details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Immunovant participated in a virtual fireside chat hosted by LifeSci Capital on December 8, 2022.","A presentation was furnished as Exhibit 99.1 and incorporated by reference.","No specific financial or pipeline data from the presentation is included in the filing text provided.","The presentation was posted for investors, but its substantive content is not available in this summary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339355,"accession_number":"0001764013-22-000139","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant unveils next-gen FcRn inhibitor IMVT-1402; Q2 net loss $47.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IMVT-1402 observed in animal study to have best-in-class IgG reduction with minimal albumin/LDL impact.","New batoclimab programs: Phase 2b in CIDP (start by end-2022) and Phase 2 in Graves' disease (early 2023).","Pro forma cash $476M after $70M October 2022 equity offering; cash runway into H2 2025.","Q2 net loss $47.9M ($0.41/sh) vs $37.7M ($0.35/sh) YoY; R&D expenses rose to $37.7M.","IMVT-1402 IND submission early 2023, initial data mid-2023; batoclimab MG and TED trials on track."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339354,"accession_number":"0001193125-22-257688","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Immunovant prices $75M stock offering at $6/share to fund IMVT-1402 development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 12.5M shares at $6.00 per share; gross proceeds ~$75M before discounts.","Investors include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF, and Commodore Capital.","Net proceeds to accelerate IMVT-1402 development, including a proposed pivotal trial.","Existing cash plus offering proceeds expected to fund company into H2 2025.","Offering expected to close Oct 6, 2022; SVB Securities and Truist Securities are joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356725,"accession_number":"0001764013-22-000118","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-09-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunovant announces next-generation anti-FcRn IMVT-1402 with promising preclinical data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IMVT-1402 showed deep IgG lowering with minimal impact on albumin and LDL in animal studies.","Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023.","Cash runway guidance into calendar year 2025 remains unchanged, including Phase 1 costs for IMVT-1402.","Composition of matter patent protection expected for IMVT-1402 through at least 2042.","Batoclimab programs in Myasthenia Gravis, Thyroid Eye Disease, CIDP and Graves' Disease continue at full speed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356724,"accession_number":"0001764013-22-000114","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunovant to start pivotal Phase 2b in CIDP in H2 2022; Phase 2 in Graves' Disease in early 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pivotal Phase 2b trial of batoclimab in CIDP to start H2 2022; initial open-label results expected H1 2024.","Phase 2 trial of batoclimab in Graves' Disease to start early 2023; initial results expected H2 2023.","Batoclimab now in five indications: MG, TED, CIDP, Graves', and wAIHA (trial design pending regulator interaction later 2022).","Data readouts expected every half-year from H2 2023 through H1 2025 across multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356723,"accession_number":"0001764013-22-000108","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunovant stockholders elect directors, ratify auditor, approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three directors elected: Peter Salzmann, Douglas Hughes, George Migausky — all with >90M votes for.","Ernst & Young LLP ratified as independent auditor for FY ending March 31, 2023 (105.8M for, 33k against).","Non-binding advisory approval of named executive officer compensation passed with 87.5M for, 14.8M against.","Approximately 91% of shares entitled to vote were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356722,"accession_number":"0001764013-22-000083","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant Q1 net loss $40.4M; initiates pivotal MG trial, TED trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $40.4M ($0.35/share) vs $30.5M ($0.31) YoY; R&D expenses up to $28.4M from $18.7M.","Cash $427M as of June 30; expects runway into calendar 2025 despite $31M in CMC/clinical payments in Q1.","Pivotal batoclimab trial in Myasthenia Gravis initiated June 2022; top-line data expected H2 2024.","FDA alignment on two pivotal trials in Thyroid Eye Disease; trials to start H2 2022, data H1 2025.","Investor call Sep 7 to announce two new batoclimab indications and third pivotal trial for 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375183,"accession_number":"0001764013-22-000057","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Immunovant gains FDA alignment for Phase 3 batoclimab trials in TED; reports FY2022 loss of $156.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA aligned on Phase 3 TED program: two placebo-controlled trials (100 patients each) initiating H2 2022; top-line data H1 2025.","Phase 3 MG trial initiation on track by end of June 2022; top-line data expected H2 2024.","Cash $493.8M as of March 31, 2022 provides runway into calendar year 2025.","FY2022 net loss $156.7M ($1.43/share) vs FY2021 $107.4M ($1.22/share); R&D spend $101.8M.","Company expects to announce two new batoclimab indications by August 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393565,"accession_number":"0001764013-22-000033","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant R&D Day presentation filed; details not fully available in text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Immunovant hosted a virtual R&D Day on March 30, 2022; presentation filed as Exhibit 99.1.","The filed exhibit contains only the title slide; no specific data or updates are extractable from the provided text.","Investors should refer to the complete presentation for pipeline and clinical trial updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393564,"accession_number":"0001764013-22-000029","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunovant Q3 net loss widens to $41.4M; cash at $527M; clinical pause continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.4M ($0.36 per share) for Dec 2021 quarter vs. $31.8M ($0.32) a year ago.","R&D expenses rose to $29.8M from $21.1M, driven by clinical study costs and manufacturing.","Cash and equivalents of $527.0M as of Dec 31, 2021; no revenue reported.","G&A expenses increased to $11.5M from $10.5M year-over-year, partly due to stock-based compensation.","Clinical trial activities remain paused due to previously announced voluntary hold."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393563,"accession_number":"0001764013-22-000007","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-01-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant to present corporate overview at J.P. Morgan Healthcare Conference on Jan 13, 2022","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Pete Salzmann to present on Thursday, January 13, 2022 at 9:45am ET.","Webcast available via investor relations section of Immunovant's website.","No new financial or clinical data announced in the press release.","Presentation is part of the 40th Annual J.P. Morgan Healthcare Conference (Jan 10-13)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393562,"accession_number":"0001764013-22-000002","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant provides Phase 3 update for batoclimab in myasthenia gravis","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate webcast held Jan 5, 2022; presentation focuses on Phase 3 development of batoclimab.","Batoclimab is the company's lead anti-FcRn antibody candidate for myasthenia gravis.","No specific clinical data or milestones were disclosed in the filing or attached presentation.","Update may include trial design, enrollment status, or regulatory timeline; details not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412093,"accession_number":"0001764013-21-000129","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2021-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant achieves FDA alignment to start Phase 3 trial for batoclimab in MG in 1H 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Division of Neurology 1 agreed to move forward; Phase 3 for batoclimab in myasthenia gravis starts 1H 2022.","Trial includes induction with 680mg and 340mg weekly subQ doses; primary efficacy: MG-ADL in AChR+ subjects at 12 weeks.","Follow-on periods will explore alternative dosing (lower maintenance, higher rescue). Safety database per FDA guidance.","Data readout expected in 2024; investor call scheduled for January 5, 2022 at 8 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412092,"accession_number":"0001764013-21-000127","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2021-11-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Immunovant enters $36M manufacturing deal with Samsung Biologics for batoclimab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Minimum purchase commitment estimated at $36M; PSA runs through Dec 31, 2029.","Immunovant can terminate if it stops all batoclimab development by Jan 2024, paying non-cancellable fees.","Samsung will manufacture batoclimab drug substance for commercial sale, including process performance qualification batches.","Agreement builds on Master Services Agreement dated April 30, 2021.","Either party may terminate for material breach, insolvency, or force majeure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412091,"accession_number":"0001764013-21-000123","cik":1764013,"company_name":"Immunovant, Inc.","ticker":"IMVT","form_type":"8-K","filed_at":"2021-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant to present corporate overview at Stifel Virtual Healthcare Conference Nov 17","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO Pete Salzmann to present at Stifel 2021 Virtual Healthcare Conference on Nov 17, 2021 at 2:00pm ET.","Webcast available on Immunovant's investor relations website.","No material financial or operational updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6896326908.1290045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-17T23:59:59+00:00|412091"}